Athyrium fund emerges as Amryt’s largest shareholder
Amryt confirmed last week that it has raised $60 million to buy rare disease drug firm Aegerion
A $3.7 billion New York investment fund has emerged as the largest shareholder in Dublin-based pharma company Amryt as a result of its takeover of Aegerion.
Athyrium Capital Management was one of a number of lenders to Aegerion, which has been acquired out of bankruptcy protection by Amryt, and will hold a 27 per cent stake in the enlarged company. Athyrium is a fund that invests in the healthcare and pharma sector.
Aegerion’s ...
